E
Xilio Therapeutics, Inc.
XLO
$0.7002
-$0.031-4.24%
E
Sell
2/11/2025Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 2/11/2025 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 2/11/2025 due to a decline in the volatility index.
D
Sell
1/27/2025Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 1/27/2025 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.3168 to -$0.2209.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 1/27/2025 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.3168 to -$0.2209.
E
Sell
10/14/2024Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 10/14/2024 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 10/14/2024 due to a decline in the volatility index.
D
Sell
9/27/2024Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 9/27/2024 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 9/27/2024 due to an increase in the volatility index.
E
Sell
9/9/2024Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 9/9/2024 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 9/9/2024 due to a decline in the volatility index.
D
Sell
8/22/2024Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 8/22/2024 due to an increase in the volatility index and solvency index. Debt to equity declined from 0.04 to 0.03.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 8/22/2024 due to an increase in the volatility index and solvency index. Debt to equity declined from 0.04 to 0.03.
E
Sell
7/26/2024Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index and total return index.
D
Sell
7/11/2024Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index.
E
Sell
6/20/2024Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index.
D
Sell
6/4/2024Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 6/4/2024 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 21.78% from -$13.43M to -$10.5M, EBIT increased 8.78% from -$18.13M to -$16.54M, and earnings per share increased from -$0.6407 to -$0.62.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 6/4/2024 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 21.78% from -$13.43M to -$10.5M, EBIT increased 8.78% from -$18.13M to -$16.54M, and earnings per share increased from -$0.6407 to -$0.62.
E
Sell
5/21/2024Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 5/21/2024 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 5/21/2024 due to a decline in the volatility index.
D
Sell
5/3/2024Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/3/2024 due to an increase in the volatility index and valuation index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/3/2024 due to an increase in the volatility index and valuation index.
E
Sell
11/13/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 4.63 to 3.53.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 4.63 to 3.53.
D
Sell
11/3/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 11/3/2023 due to an increase in the total return index and volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 11/3/2023 due to an increase in the total return index and volatility index.
E
Sell
10/19/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
D
Sell
10/4/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 10/4/2023 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 10/4/2023 due to an increase in the volatility index.
E
Sell
9/14/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index.
D
Sell
8/30/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 8/30/2023 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 8/30/2023 due to an increase in the volatility index.
E
Sell
8/15/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 5.76 to 4.63, and debt to equity increased from 0.11 to 0.12.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 5.76 to 4.63, and debt to equity increased from 0.11 to 0.12.
D
Sell
7/31/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 7/31/2023 due to an increase in the total return index and volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 7/31/2023 due to an increase in the total return index and volatility index.
E
Sell
7/11/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 7/11/2023 due to a decline in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 7/11/2023 due to a decline in the volatility index and total return index.
D
Sell
6/23/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 6/23/2023 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 6/23/2023 due to an increase in the volatility index.
E
Sell
6/7/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index and total return index.
D
Sell
5/22/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/22/2023 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/22/2023 due to an increase in the volatility index.
E
Sell
5/17/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 5/17/2023 due to a decline in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 5/17/2023 due to a decline in the volatility index and total return index.
D
Sell
5/1/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/1/2023 due to an increase in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/1/2023 due to an increase in the volatility index and total return index.
E
Sell
4/13/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 4/13/2023 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 4/13/2023 due to a decline in the volatility index.
D
Sell
3/29/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
3/7/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 3/7/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 8.26 to 5.7, EBIT declined 14.65% from -$20.21M to -$23.17M, and earnings per share declined from -$0.7223 to -$0.8207.
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 3/7/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 8.26 to 5.7, EBIT declined 14.65% from -$20.21M to -$23.17M, and earnings per share declined from -$0.7223 to -$0.8207.
D
Sell
2/9/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
1/24/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index and total return index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index and total return index.
D
Sell
1/6/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 1/6/2023 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 1/6/2023 due to a decline in the volatility index.
D
Sell
12/19/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 12/19/2022 due to an increase in the volatility index.
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 12/19/2022 due to an increase in the volatility index.
D
Sell
12/2/2022Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 12/2/2022 due to a decline in the volatility index.
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 12/2/2022 due to a decline in the volatility index.
D
Sell
11/16/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 11/16/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.8988 to -$0.7223, and EBIT increased 17.7% from -$24.55M to -$20.21M.
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 11/16/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.8988 to -$0.7223, and EBIT increased 17.7% from -$24.55M to -$20.21M.
D
Sell
7/1/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E on 07/01/2022.
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E on 07/01/2022.
E
Sell
4/1/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index and growth index. The quick ratio increased from 7.75 to 15.5, earnings per share increased from -$21.2746 to -$0.9822, and operating cash flow increased 17.17% from -$20.72M to -$17.16M.
Xilio Therapeutics, Inc. (XLO) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index and growth index. The quick ratio increased from 7.75 to 15.5, earnings per share increased from -$21.2746 to -$0.9822, and operating cash flow increased 17.17% from -$20.72M to -$17.16M.
E
Sell
1/18/2022None
Xilio Therapeutics, Inc. (XLO) was downgraded to E- from U on 01/18/2022.
Xilio Therapeutics, Inc. (XLO) was downgraded to E- from U on 01/18/2022.
NASDAQ
04/03/2025 4:00PM Eastern
Quotes delayed
